80 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Reviewers” means independent persons nominated by CRH or the Charity for the purpose of monitoring and reviewing work funded by the Charity … non-recoverable taxes or charges, including Value Added Tax.
“Expert” means a suitably qualified independent expert appointed by agreement between
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
(“IRB”) or independent ethics committee approval at each clinical trial site;
delays in recruiting suitable subjects to participate in Tenet’s … to continue to rely upon third parties, including independent investigators, medical institutions, CROs, and strategic partners, to help conduct
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Property rights that (i) ProBioGen holds or controls before the Effective Date and/or (ii) that are developed by ProBioGen independent from the Services … of ProBioGen, ValenzaBio shall permit and shall cause its Affiliates and Sub-Licensees to permit, an independent certified public ac-counting firm
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
such firm is unable or unwilling to act, another nationally recognized independent (as to Buyer and Seller) accounting firm reasonably acceptable … ) in a jurisdiction, any pharmaceutical/biologic product that: (a) is sold in such jurisdiction under an independent marketing authorization by a Third Party
8-K
EX-99.5
nnailif
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
p0y4pm6kitrcikmt
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-23.1
jznwy061rv53 38py8i
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.4
w0dlvz6vi5r9u ey
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
o5fooet4brsng9
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
ybth07hv
26 Jun 24
Submission of Matters to a Vote of Security Holders
4:23pm
DEFA14A
0vtoz657
14 Jun 24
Additional proxy soliciting materials
5:02pm
8-K
EX-10.1
hsw tp47j0njm1zb
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
lopc69ah2nvyr0r3f7
4 Jun 24
Proxy related to merger
8:00am
PREM14A
50p9gyp19puz
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
5nfbte8hdn3as
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
171kjuomzlnogctfqjh
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
axr 56dpq6yyew5ao
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
5l3hr6casfhhwloe5 kk
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am